-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex reports positive biomarker data for Reqorsa gene therapy in lung cancer patients

PUBT·04/22/2026 11:04:40
Listen to the news
Genprex reports positive biomarker data for Reqorsa gene therapy in lung cancer patients
  • Genprex flagged positive clinical findings from studies of predictive biomarkers in lung cancer patients treated with Reqorsa gene therapy.
  • Data were not yet presented; results are scheduled for release at 2026 ASCO Annual Meeting on May 29–June 2 in Chicago.
  • Biomarker work is aimed at improving patient selection for Genprex lung cancer trials, potentially supporting stronger treatment responses.
  • Reqorsa remains Genprex lead oncology asset, currently in two clinical trials for non-small cell lung cancer, small cell lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604220700PR_NEWS_USPR_____DA40326) on April 22, 2026, and is solely responsible for the information contained therein.